Cosmetic hexapeptide · Fact sheet
Argireline
Also known as Acetyl hexapeptide-8 · Acetyl hexapeptide-3
Argireline is an acetylated hexapeptide studied in topical wrinkle formulations. Small cosmetic trials report some appearance changes, but it is not equivalent to botulinum toxin and does not have an established injectable treatment regimen.
What is Argireline?
Acetyl hexapeptide-8 has also appeared under the older acetyl hexapeptide-3 naming convention.
A cosmetic emulsion contains a delivery vehicle; its findings cannot be transferred to every serum or route.
Benefits & claims
Interest centers on skin or hair appearance. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- The four-week trial found improvements in selected wrinkle-appearance measures.
- Laboratory delivery differed among emulsion types.
- A proposed SNAP-25/SNARE-related mechanism does not establish equivalence in potency, delivery or effect to botulinum toxin.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Argireline. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Acetyl hexapeptide-8 has also appeared under the older acetyl hexapeptide-3 naming convention.
Formulation differences
- A cosmetic emulsion contains a delivery vehicle; its findings cannot be transferred to every serum or route.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Small topical studies cannot establish uncommon irritation, allergy or long-term effects across formulations.
- Topical tolerability and appearance results do not establish systemic or injectable safety.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA 60-person short randomized study reported wrinkle improvements. Skin-penetration work shows that the vehicle affects delivery, limiting cross-product comparisons.
Studies
60-person, four-week topical randomized study.
Porcine-skin delivery experiments showing vehicle effects.
Original design and small cosmetic-effect investigation.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Argireline has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.
- Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure.
- A synthetic hexapeptide (Argireline) with antiwrinkle activity.
- FDA: cosmetics and U.S. law
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
A proposed SNAP-25/SNARE-related mechanism does not establish equivalence in potency, delivery or effect to botulinum toxin.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.
60-person, four-week topical randomized study.
- pubmedTopical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure.
Porcine-skin delivery experiments showing vehicle effects.
- pubmedA synthetic hexapeptide (Argireline) with antiwrinkle activity.
Original design and small cosmetic-effect investigation.
- fdaFDA: cosmetics and U.S. law
Cosmetic ingredients generally do not receive FDA premarket approval; disease and structure/function claims can invoke drug regulation.